Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Short Bowel Syndrome and Intestinal Failure
NCT07297238Completed
- Sponsor
- Jinling Hospital
- Start
- Jan 2026
- Primary completion
- May 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of semaglutide in short bowel syndrome (SBS) and intestinal failure (IF) (2 arms), sponsored by Jinling Hospital. Primary endpoint: Serum Biomarkers of Intestinal Barrier Function at 28 days. Started Jan 2026; status: completed.
02
Drugs
03
Conditions
short bowel syndrome (SBS)intestinal failure (IF)
Beyond the preview
Go deeper on NCT07297238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297238.